How Briumvi Works Against MS
Briumvi (ublituximab-xiiy) treats relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS, by targeting CD20-positive B cells. It binds to the CD20 protein on these immune cells, marking them for destruction via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis. This depletes B cells, which drive inflammation and myelin damage in MS by producing autoantibodies and promoting pro-inflammatory T cells.[1][2]
Briumvi's Dosing Schedule
Administered as two hourly IV infusions: 150 mg on day 1, 450 mg two weeks later, then 450 mg every 24 weeks. This infrequent schedule—once or twice a year after initiation—sets it apart from rivals like Ocrevus, which requires dosing every six months.[1][3]
How It Compares to Ocrevus
Both are anti-CD20 monoclonal antibodies, but Briumvi uses a glycoengineered design for stronger antibody-dependent cytotoxicity and faster B-cell depletion (over 95% within a week vs. Ocrevus's slower onset). Clinical trials (ULTIMATE I/II) showed it reduced annualized relapse rates by 59-66% vs. teriflunomide and cut Gd+ lesions by up to 97%, with similar MRI outcomes to Ocrevus but a shorter infusion time.[2][4]
Common Side Effects Patients Report
Infusion reactions (up to 48%, mostly mild in first doses), infections (upper respiratory or urinary tract), and reduced immunoglobulins occur frequently. Serious risks include progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation, and weakened immunity to infections—patients need HBV screening and vaccinations beforehand. Long-term data is limited as it's FDA-approved since December 2022.[1][3]
Who Makes Briumvi and Patent Timeline
TG Therapeutics develops and markets it. Key U.S. patents (e.g., composition-of-matter and method-of-use) extend protection into the late 2030s, per DrugPatentWatch.com analysis—no generics expected before 2036 barring challenges.[5]
Sources
[1]: Briumvi Prescribing Information (FDA)
[2]: NEJM: ULTIMATE I/II Trials
[3]: MS Society: Briumvi Overview
[4]: TG Therapeutics Press Release
[5]: DrugPatentWatch: Briumvi Patents